# US 2013/0295111 A1 · Methods and compositions for treating disorders associated with hyperactive immune system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295111 A1
- Document ID: US20130295111A1
- Status: Published application
- Kind: A1
- Application number: 13/816,121
- Filed: 2011-08-09
- Published: 2013-11-07
- Earliest claimed: 2010-08-10
- Assignees: The Scripps Research Institute
- Inventors: Rosa Ana Gonzalez-Quintial; Roberto G. Baccala; Brian R. Lawson; Argyrios N. Theofilopoulos
- Web page: https://patentgrep.com/patent/US20130295111A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides methods and compositions for treating disorders associated with hyperactive immune responses. The invention also provides methods for lithibiting activation of CD4+ T cells and/or suppressing proliferation other overactivated T cells (e.g., CD4CD8 T cells). These methods typically involve the administration to the subject a therapeutically effective amount of a compound that lithibits or suppresses IL-7 signaling or IL- 15 signaling.

## Claims

### Claim 1

A method of treating or alleviating the symptoms of a disorder associated with a hyperactive immune system in a subject, comprising administering to the subject a therapeutically effective amount of a compound that inhibits or suppresses IL-7 signaling or IL-15 signaling, thereby treating or alleviating the symptoms of a disorder associated with a hyperactive immune system in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound inhibits or suppresses IL-7 signaling.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound down-regulates expression or cellular level of IL-7.

### Claim 4 (depends on 3)

The method of claim 3, wherein the compound is an inhibitory polynucleotide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound blocks signaling activities of IL-7 receptor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the compound is an antagonist antibody specific for IL-7Rα.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disorder associated with hyperactive immune response is an autoimmune disease.

### Claim 8 (depends on 7)

The method of claim 7, wherein the autoimmune disease is lupus or multiple sclerosis.

### Claim 9

A method of inhibiting activation of CD4+ T cells in a subject, comprising administering to the subject a therapeutically effective amount of a compound that inhibits or suppresses IL-7 signaling, thereby inhibiting activation of CD4+ T cells in the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the compound down-regulates expression or cellular level of IL-7.

### Claim 11 (depends on 10)

The method of claim 10, wherein the compound is an inhibitory polynucleotide.

### Claim 12 (depends on 9)

The method of claim 9, wherein the compound blocks signaling activities of IL-7 receptor.

### Claim 13 (depends on 12)

The method of claim 12, wherein the compound is an antagonist antibody specific for IL-7Rα.

### Claim 14 (depends on 9)

The method of claim 9, wherein the subject suffers from an inflammatory disorder.

### Claim 15 (depends on 14)

The method of claim 14, wherein the inflammatory disorder is multiple sclerosis.

### Claim 16 (depends on 15)

The method of claim 15, wherein the treatment is to prevent relapse of multiple sclerosis in the subject.

### Claim 17

A method of inhibiting proliferation of an overactivated T cell in a subject, comprising administering to the subject a therapeutically effective amount of a compound that inhibits or suppresses IL-7 signaling or IL-15 signaling, thereby inhibiting proliferation the overactivated T cell in the subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound inhibits or suppresses IL-7 signaling.

### Claim 19 (depends on 18)

The method of claim 18, wherein the compound down-regulates expression or cellular level of IL-7.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound is an inhibitory polynucleotide.

### Claim 21 (depends on 19)

The method of claim 19, wherein the compound is a siRNA specific for IL-7.

### Claim 22 (depends on 18)

The method of claim 18, wherein the compound blocks signaling activities of IL-7 receptor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the compound is an antagonist antibody specific for IL-7Rα.

### Claim 24 (depends on 17)

The method of claim 17, wherein the subject suffers from an autoimmune disease.

### Claim 25 (depends on 24)

The method of claim 24, wherein the autoimmune disease is lupus or multiple sclerosis.

### Claim 26 (depends on 17)

The method of claim 17, wherein the overactivated T cell is CD4−CD8− T cell.
